Clinical Trial Detail

NCT ID NCT03259503
Title Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

diffuse large B-cell lymphoma

lymphoma

Hodgkin's lymphoma

non-Hodgkin lymphoma

Therapies

Busulfan

Olaparib

Vorinostat

Palifermin

Gemcitabine

Melphalan

Dexamethasone

Pyridoxine

Rituximab

Age Groups: adult child

No variant requirements are available.